CHRNA7 and neurodegenerative disease: As such, glial α7 nAChRs are considered potential therapeutic targets in neurodegenerative diseases [104]; furthermore, α7 nAChR agonists have been reported to provide neuroprotection against various toxic insults including β-amyloid [105], MPTP (in vivo) and MPP+- or LPS (in vitro) [106].